|
1
|
Minlikeeva AN, Freudenheim JL, Cannioto
RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G,
Segal BH, et al: Australian Ovarian Cancer Study Group; Ovarian
Cancer Association Consortium: History of hypertension, heart
disease, and diabetes and ovarian cancer patient survival: Evidence
from the ovarian cancer association consortium. Cancer Causes
Control. 28:469–486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schorge JO, Clark RM, Lee SI and Penson
RT: Primary debulking surgery for advanced ovarian cancer: Are you
a believer or a dissenter? Gynecol Oncol. 135:595–605. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi T, Wang P, Xie C, Yin S, Shi D, Wei C,
Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations
in ovarian cancer patients from China: Ethnic-related mutations in
BRCA1 associated with an increased risk of ovarian cancer. Int J
Cancer. 140:2051–2059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogel TJ, Goodman MT, Li AJ and Jeon CY:
Statin treatment is associated with survival in a nationally
representative population of elderly women with epithelial ovarian
cancer. Gynecol Oncol. 146:340–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA;
Gynecologic Oncology Group, : Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel S, Kumar L and Singh N: Metformin
and epithelial ovarian cancer therapeutics. Cell Oncol (Dordr).
38:365–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spindel ER: Muscarinic receptor agonists
and antagonists: Effects on cancer. Handb Exp Pharmacol.
208:451–468. 2012. View Article : Google Scholar
|
|
8
|
Hua N, Wei X, Liu X, Ma X, He X, Zhuo R,
Zhao Z, Wang L, Yan H, Zhong B, et al: A novel muscarinic
antagonist R2HBJJ inhibits non-small cell lung cancer cell growth
and arrests the cell cycle in G0/G1. PLoS One. 7:e531702012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oppitz M, Möbus V, Brock S and Drews U:
Muscarinic receptors in cell lines from ovarian carcinoma: Negative
correlation with survival of patients. Gynecol Oncol. 85:159–164.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah N, Khurana S, Cheng K and Raufman JP:
Muscarinic receptors and ligands in cancer. Am J Physiol Cell
Physiol. 296:C221–C232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song P, Sekhon HS, Lu A, Arredondo J,
Sauer D, Gravett C, Mark GP, Grando SA and Spindel ER: M3
muscarinic receptor antagonists inhibit small cell lung carcinoma
growth and mitogen-activated protein kinase phosphorylation induced
by acetylcholine secretion. Cancer Res. 67:3936–3944. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ni H, Soe Z and Moe S: Aclidinium bromide
for stable chronic obstructive pulmonary disease. Cochrane Database
Syst Rev. 19:CD0105092014.
|
|
13
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reid DJ and Carlson AA: Clinical use of
aclidinium in patients with COPD. Int J Chron Obstruct Pulmon Dis.
9:369–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fritz S, Wessler I, Breitling R,
Rossmanith W, Ojeda SR, Dissen GA, Amsterdam A and Mayerhofer A:
Expression of muscarinic receptor types in the primate ovary and
evidence for nonneuronal acetylcholine synthesis. J Clin Endocrinol
Metab. 86:349–354. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayerhofer A and Kunz L: A non-neuronal
cholinergic system of the ovarian follicle. Ann Anat. 187:521–528.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ami N, Koga K, Fushiki H, Ueno Y, Ogino Y
and Ohta H: Selective M3 muscarinic receptor antagonist inhibits
small-cell lung carcinoma growth in a mouse orthotopic xenograft
model. J Pharmacol Sci. 116:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pacini L, De Falco E, Di Bari M, Coccia A,
Siciliano C, Ponti D, Pastore AL, Petrozza V, Carbone A, Tata AM,
et al: M2 muscarinic receptors inhibit cell proliferation and
migration in urothelial bladder cancer cells. Cancer Biol Ther.
15:1489–1498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park YS and Cho NJ: Enhanced proliferation
of SNU-407 human colon cancer cells by muscarinic acetylcholine
receptors. BMB Rep. 41:803–807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Russo P, Del Bufalo A, Milic M, Salinaro
G, Fini M and Cesario A: Cholinergic receptors as target for cancer
therapy in a systems medicine perspective. Curr Mol Med.
14:1126–1138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Batra S, Popper LD and Iosif CS:
Characterisation of muscarinic cholinergic receptors in human
ovaries, ovarian tumours and tumour cell lines. Eur J Cancer.
29A:1–1306. 1993.
|
|
22
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cazzola M: Aclidinium bromide, a novel
long-acting muscarinic M3 antagonist for the treatment of COPD.
Curr Opin Investig Drugs. 10:482–490. 2009.PubMed/NCBI
|
|
25
|
Shayesteh L, Lu Y, Kuo WL, Baldocchi R,
Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW:
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet.
21:99–102. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng JQ, Ruggeri B, Klein WM, Sonoda G,
Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human
pancreatic cells and inhibition of AKT2 expression and
tumorigenicity by antisense RNA. Proc Natl Acad Sci USA.
93:3636–3641. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu W, Slomovitz BM, Soliman PT, Schmeler
KM, Celestino J, Milam MR and Lu KH: Correlation of cyclin D1 and
cyclin D3 overexpression with the loss of PTEN expression in
endometrial carcinoma. Int J Gynecol Cancer. 16:1668–1672. 2006.
View Article : Google Scholar : PubMed/NCBI
|
